WSO - April 2024 - 442

1215660
WSO
International Journal of StrokeOzkan et al.
Research
Prevalence, patterns, and predictors
of patient-reported non-motor
outcomes at 30 days after acute stroke:
Prospective observational hospital
cohort study
Hatice Ozkan1,2 , Gareth Ambler3, Gargi Banerjee1,2,4
Simone Browning2, Alex P Leff1,2 , Nick S Ward1,2,
Robert J Simister1,2 and David J Werring1,2
Abstract
Background: Adverse non-motor outcomes are common after acute stroke and likely to substantially affect quality
of life, yet few studies have comprehensively assessed their prevalence, patterns, and predictors across multiple health
domains.
Aims: We aimed to identify the prevalence, patterns, and the factors associated with non-motor outcomes 30 days
after stroke.
Methods: This prospective observational hospital cohort study-Stroke Investigation in North and Central London
(SIGNAL)-identified patients with acute ischemic stroke or intracerebral hemorrhage (ICH) admitted to the Hyperacute
Stroke Unit (HASU) at University College Hospital (UCH), London, between August 1, 2018 and August 31, 2019.
We assessed non-motor outcomes (anxiety, depression, fatigue, sleep, participation in social roles and activities, pain,
bowel function, and bladder function) at 30-day follow-up using the Patient-Reported Outcome Measurement Information
System-Version 29 (PROMIS-29) scale and Barthel Index scale.
Results: We obtained follow-up data for 605/719 (84.1%) eligible patients (mean age 72.0 years; 48.3% female; 521 with
ischemic stroke, 84 with ICH). Anxiety (57.0%), fatigue (52.7%), bladder dysfunction (50.2%), reduced social participation
(49.2%), and pain (47.9%) were the commonest adverse non-motor outcomes. The rates of adverse non-motor
outcomes in ⩾ 1, ⩾ 2 and ⩾ 3 domains were 89%, 66.3%, and 45.8%, respectively; in adjusted analyses, stroke due to ICH
(compared to ischemic stroke) and admission stroke severity were the strongest and most consistent predictors. There
were significant correlations between bowel dysfunction and bladder dysfunction (κ = 0.908); reduced social participation
and bladder dysfunction (κ = 0.844); and anxiety and fatigue (κ = 0.613). We did not identify correlations for other
pairs of non-motor domains.
Conclusion: Adverse non-motor outcomes were very common at 30 days after stroke, affecting nearly 90% of evaluated
patients in at least one health domain, about two-thirds in two or more domains, and almost 50% in three or more
domains. Stroke due to ICH and admission stroke severity were the strongest and most consistent predictors. Adverse
outcomes occurred in pairs of domains, such as with anxiety and fatigue. Our findings emphasize the importance of a
multi-domain approach to effectively identify adverse non-motor outcomes after stroke to inform the development of
more holistic patient care pathways after stroke.
1UCL Queen Square Institute of Neurology, London, UK
2 Hyper Acute Stroke Unit, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust,
London, UK
3Department of Statistical Science, University College London, London, UK
4MRC Prion Unit at UCL, Institute of Prion Diseases, London, UK
Corresponding author:
David Werring, Hyper Acute Stroke Unit, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS
Foundation Trust, Queen Square, London, WC1N 3BG, UK.
Email: d.werring@ucl.ac.uk
International Journal of Stroke, 19(4)
,
International Journal of Stroke
2024, Vol. 19(4) 442 -451
© 2023 World Stroke Organization
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/17474930231215660
journals.sagepub.com/home/wso
https://doi.org/10.1177/17474930231215660
http://www.sagepub.com/journals-permissions https://www.doi.org/10.1177/17474930231215660 http://journals.sagepub.com/home/wso

WSO - April 2024

Table of Contents for the Digital Edition of WSO - April 2024

Content
WSO - April 2024 - Cover1
WSO - April 2024 - Cover2
WSO - April 2024 - 373
WSO - April 2024 - Content
WSO - April 2024 - 375
WSO - April 2024 - 376
WSO - April 2024 - 377
WSO - April 2024 - 378
WSO - April 2024 - 379
WSO - April 2024 - 380
WSO - April 2024 - 381
WSO - April 2024 - 382
WSO - April 2024 - 383
WSO - April 2024 - 384
WSO - April 2024 - 385
WSO - April 2024 - 386
WSO - April 2024 - 387
WSO - April 2024 - 388
WSO - April 2024 - 389
WSO - April 2024 - 390
WSO - April 2024 - 391
WSO - April 2024 - 392
WSO - April 2024 - 393
WSO - April 2024 - 394
WSO - April 2024 - 395
WSO - April 2024 - 396
WSO - April 2024 - 397
WSO - April 2024 - 398
WSO - April 2024 - 399
WSO - April 2024 - 400
WSO - April 2024 - 401
WSO - April 2024 - 402
WSO - April 2024 - 403
WSO - April 2024 - 404
WSO - April 2024 - 405
WSO - April 2024 - 406
WSO - April 2024 - 407
WSO - April 2024 - 408
WSO - April 2024 - 409
WSO - April 2024 - 410
WSO - April 2024 - 411
WSO - April 2024 - 412
WSO - April 2024 - 413
WSO - April 2024 - 414
WSO - April 2024 - 415
WSO - April 2024 - 416
WSO - April 2024 - 417
WSO - April 2024 - 418
WSO - April 2024 - 419
WSO - April 2024 - 420
WSO - April 2024 - 421
WSO - April 2024 - 422
WSO - April 2024 - 423
WSO - April 2024 - 424
WSO - April 2024 - 425
WSO - April 2024 - 426
WSO - April 2024 - 427
WSO - April 2024 - 428
WSO - April 2024 - 429
WSO - April 2024 - 430
WSO - April 2024 - 431
WSO - April 2024 - 432
WSO - April 2024 - 433
WSO - April 2024 - 434
WSO - April 2024 - 435
WSO - April 2024 - 436
WSO - April 2024 - 437
WSO - April 2024 - 438
WSO - April 2024 - 439
WSO - April 2024 - 440
WSO - April 2024 - 441
WSO - April 2024 - 442
WSO - April 2024 - 443
WSO - April 2024 - 444
WSO - April 2024 - 445
WSO - April 2024 - 446
WSO - April 2024 - 447
WSO - April 2024 - 448
WSO - April 2024 - 449
WSO - April 2024 - 450
WSO - April 2024 - 451
WSO - April 2024 - 452
WSO - April 2024 - 453
WSO - April 2024 - 454
WSO - April 2024 - 455
WSO - April 2024 - 456
WSO - April 2024 - 457
WSO - April 2024 - 458
WSO - April 2024 - 459
WSO - April 2024 - 460
WSO - April 2024 - 461
WSO - April 2024 - 462
WSO - April 2024 - 463
WSO - April 2024 - 464
WSO - April 2024 - 465
WSO - April 2024 - 466
WSO - April 2024 - 467
WSO - April 2024 - 468
WSO - April 2024 - 469
WSO - April 2024 - 470
WSO - April 2024 - 471
WSO - April 2024 - 472
WSO - April 2024 - 473
WSO - April 2024 - 474
WSO - April 2024 - 475
WSO - April 2024 - 476
WSO - April 2024 - 477
WSO - April 2024 - 478
WSO - April 2024 - Cover3
WSO - April 2024 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com